NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Forecast, Price & News $66.87 +0.83 (+1.26%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$66.80▼$67.8550-Day Range$65.49▼$72.7652-Week Range$50.46▼$73.17Volume255,159 shsAverage Volume236,720 shsMarket Capitalization$11.16 billionP/E Ratio19.33Dividend Yield0.61%Price Target$70.00 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Dr. Reddy's Laboratories MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside4.7% Upside$70.00 Price TargetShort InterestBearish1.04% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.52Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth8.97%From $3.79 to $4.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.58 out of 5 starsMedical Sector892nd out of 972 stocksPharmaceutical Preparations Industry416th out of 449 stocks 1.0 Analyst's Opinion Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 2 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.00, Dr. Reddy's Laboratories has a forecasted upside of 4.7% from its current price of $66.87.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.04% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 8.07%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.62%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories has only been increasing its dividend for 4 years.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 11.85%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 9.93% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RDY. Previous Next 2.5 News and Social Media Coverage News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.Search Interest1 people have searched for RDY on MarketBeat in the last 30 days. MarketBeat FollowsOnly 3 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 12.42% of the stock of Dr. Reddy's Laboratories is held by institutions. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 8.97% in the coming year, from $3.79 to $4.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 19.33, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 19.33, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.20.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 1.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dr. Reddy's Laboratories (NYSE:RDY) StockDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Read More RDY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDY Stock News HeadlinesSeptember 29, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo PharmaceuticalsSeptember 26, 2023 | finance.yahoo.comDoctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerOctober 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 26, 2023 | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average of $61.95September 25, 2023 | finance.yahoo.comWhy Doctor Reddy's (RDY) is a Top Growth Stock for the Long-TermSeptember 18, 2023 | finance.yahoo.comHere is Why Growth Investors Should Buy Doctor Reddy's (RDY) NowSeptember 13, 2023 | finance.yahoo.comZacks.com featured highlights Caterpillar, KB Home, Walmart, Dr. Reddy's Laboratories and FedExSeptember 8, 2023 | msn.comThese 3 Low-Beta Stocks Sport High GrowthOctober 1, 2023 | Stansberry Research (Ad)U.S. "Shadow Banks" About to Blow up again?Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.August 31, 2023 | finance.yahoo.comLooking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid ChoiceAugust 18, 2023 | msn.comHere's Why You Should Add Dr. Reddy's (RDY) to Your PortfolioAugust 14, 2023 | finance.yahoo.comZacks Industry Outlook Highlights Amphastar Pharmaceuticals, Dr. Reddy's Laboratories and Teva PharmaceuticalAugust 10, 2023 | msn.comDr. Reddy's launches generic version of Kombiglyze XR in USAugust 10, 2023 | seekingalpha.comDr. Reddy's Laboratories Limited 2024 Q1 - Results - Earnings Call PresentationJuly 28, 2023 | msn.comChart of the Day: What's Cooking at Dr. Reddy's LabJuly 28, 2023 | finance.yahoo.comDr. Reddy's (RDY) Q1 Earnings and Revenues Beat EstimatesJuly 27, 2023 | finance.yahoo.comDr. Reddy’s Laboratories Limited (NYSE:RDY) Q1 2024 Earnings Call TranscriptJuly 27, 2023 | chron.comDoctor Reddy's: Fiscal Q1 Earnings SnapshotJuly 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Dr Reddy’s Laboratories (RDY), LivaNova (LIVN) and Thermo Fisher (TMO)July 27, 2023 | markets.businessinsider.comDr Reddys Laboratories earnings preview: what Wall Street is expectingJuly 27, 2023 | reuters.comIndia's Dr.Reddy's posts 18% rise in Q1 profit on strong generic drugs salesJuly 12, 2023 | finance.yahoo.comDr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRAJune 14, 2023 | marketwatch.comDr. Reddy's Laboratories falls Wednesday, underperforms marketJune 7, 2023 | seekingalpha.comDr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate BuyJune 6, 2023 | finance.yahoo.comDr. Reddy's (RDY) Meets Goals in Actemra Biosimilar StudyMay 24, 2023 | finance.yahoo.comZacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva PharmaceuticalMay 10, 2023 | finance.yahoo.comDr. Reddy’s Q4 & FY23 Financial ResultsSee More Headlines Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address RDY Company Calendar Last Earnings7/26/2023Ex-Dividend for 7/28 Dividend7/28/2023Dividend Payable7/28/2023Today10/01/2023Next Earnings (Estimated)10/27/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:RDY CUSIPN/A CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees25,863Year Founded1984Price Target and Rating Average Stock Price Forecast$70.00 High Stock Price Forecast$70.00 Low Stock Price Forecast$70.00 Forecasted Upside/Downside+4.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$3.46 Trailing P/E Ratio19.33 Forward P/E Ratio17.64 P/E Growth1.95Net Income$548 million Net Margins18.11% Pretax Margin24.35% Return on Equity20.94% Return on Assets15.04% Debt Debt-to-Equity Ratio0.02 Current Ratio2.60 Quick Ratio1.95 Sales & Book Value Annual Sales$261.11 billion Price / Sales0.04 Cash Flow$4.21 per share Price / Cash Flow15.87 Book Value$16.87 per share Price / Book3.96Miscellaneous Outstanding Shares166,844,000Free Float163,507,000Market Cap$11.16 billion OptionableOptionable Beta0.54 Social Links 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Gunupati Venkateswara Prasad B.E. (Age 63)Co-Chairman, MD & Member of Management Council Comp: $2.26MMr. Kallam Satish Reddy B.Tech. (Age 56)M.S., Chairman & Member of the Management Council Comp: $1.39MMr. Erez Israeli M.B.A. (Age 55)CEO & Member of the Management Council Mr. Parag Agarwal (Age 56)CFO & Member of Management Council Mr. Deepak Sapra M.B.A. (Age 48)CEO of API & Services & Member of Management Council Mr. Venkata Ramana Motupalli M.B.A. (Age 54)MBA, CEO of Branded Markets - India & Emerging Countries and Member of Management Council Ms. Archana Bhaskar B.Sc. (Age 56)M.B.A., EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council Mr. Sanjay Sharma B.Tech. (Age 55)Exec. VP, Global Head of Global Manufacturing & Member of Management Council Mr. Marc Kikuchi B.A. (Age 54)M.B.A., CEO of North America Generics & Member of Management Council Mr. Patrick Aghanian B.A. (Age 58)M.B.A., CEO of European Generics & Member of Management Council More ExecutivesKey CompetitorsUnited TherapeuticsNASDAQ:UTHRLegend BiotechNASDAQ:LEGNSarepta TherapeuticsNASDAQ:SRPTVerona PharmaNASDAQ:VRNAViatrisNASDAQ:VTRSView All CompetitorsInstitutional OwnershipMondrian Investment Partners LTDSold 22,514 shares on 9/20/2023Ownership: 0.160%Osaic Holdings Inc.Sold 1,320 shares on 8/21/2023Ownership: 0.003%Orion Portfolio Solutions LLCSold 11,365 shares on 8/17/2023Ownership: 0.005%West Family Investments Inc.Bought 11,538 shares on 8/16/2023Ownership: 0.007%Stifel Financial CorpSold 222 shares on 8/15/2023Ownership: 0.003%View All Institutional Transactions RDY Stock - Frequently Asked Questions Should I buy or sell Dr. Reddy's Laboratories stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares. View RDY analyst ratings or view top-rated stocks. What is Dr. Reddy's Laboratories' stock price forecast for 2023? 6 equities research analysts have issued 12 month price targets for Dr. Reddy's Laboratories' stock. Their RDY share price forecasts range from $70.00 to $70.00. On average, they expect the company's stock price to reach $70.00 in the next year. This suggests a possible upside of 4.7% from the stock's current price. View analysts price targets for RDY or view top-rated stocks among Wall Street analysts. How have RDY shares performed in 2023? Dr. Reddy's Laboratories' stock was trading at $51.75 at the start of the year. Since then, RDY stock has increased by 29.2% and is now trading at $66.87. View the best growth stocks for 2023 here. When is Dr. Reddy's Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023. View our RDY earnings forecast. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Limited (NYSE:RDY) posted its earnings results on Wednesday, July, 26th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.32. The company had revenue of $820.20 million for the quarter, compared to analysts' expectations of $790.67 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 20.94% and a net margin of 18.11%. How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories? Dr. Reddy's Laboratories declared an annual dividend on Tuesday, July 18th. Shareholders of record on Friday, January 1st will be given a dividend of $0.4877 per share on Friday, July 28th. This represents a dividend yield of 0.7%. The ex-dividend date is Friday, July 28th. This is an increase from the stock's previous annual dividend of $0.33. Read our dividend analysis for RDY. What ETFs hold Dr. Reddy's Laboratories' stock? ETFs with the largest weight of Dr. Reddy's Laboratories (NYSE:RDY) stock in their portfolio include ALPS Emerging Sector Dividend Dogs ETF (EDOG), First Trust BICK Index Fund (BICK), Putnam PanAgora ESG Emerging Markets Equity ETF (PPEM), Inspire Tactical Balanced ETF (RISN), Inspire Fidelis Multi Factor ETF (FDLS), Hartford Multifactor Emerging Markets ETF (ROAM) and Invesco S&P Emerging Markets Low Volatility ETF (EELV).SPDR Bloomberg SASB Emerging Markets ESG Select ETF (REMG). Is Dr. Reddy's Laboratories a good dividend stock? Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.41 per share and currently has a dividend yield of 0.62%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 11.85%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 9.93% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RDY. What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO? 528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE). What is Dr. Reddy's Laboratories' stock symbol? Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY." How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dr. Reddy's Laboratories' stock price today? One share of RDY stock can currently be purchased for approximately $66.87. How much money does Dr. Reddy's Laboratories make? Dr. Reddy's Laboratories (NYSE:RDY) has a market capitalization of $11.16 billion and generates $261.11 billion in revenue each year. The company earns $548 million in net income (profit) each year or $3.46 on an earnings per share basis. How many employees does Dr. Reddy's Laboratories have? The company employs 25,863 workers across the globe. How can I contact Dr. Reddy's Laboratories? Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The official website for the company is www.drreddys.com. The company can be reached via phone at 914049002900, via email at amita@drreddys.com, or via fax at 91-40-4900-2999. This page (NYSE:RDY) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.